title: Pediatric liver transplant with Campath 1H induction--Preliminary report.
abstract: Since Campath 1H (C1H) has been successfully used in adult liver transplant recipients since 2001 in our program, we started to use it in children.
  
  
  METHODS
  C1H induction was employed in 10 children with autoimmune hepatitis (AIH) (n = 6), primary sclerosing cholangitis (PSC) (n = 1), biliary atresia (n = 1), glycogen storage disease (n = 1), and Wilson's disease. Eight were primary transplants, and two retransplants. Patients ages ranged from 5 to 17 years. C1H was administered at a dose of 0.3 mg/kg on days 0, 4, and 7. Tacrolimus level was maintained at 5 to 10 ng/mL. No patient received maintenance steroids posttransplantation except two who were on steroid therapy at the time transplant. They were prescribed small doses of maintenance steroids. Median follow-up of C1H recipients was 679 days (range 115-1143).
  
  
  RESULTS
  Postoperative courses were mostly uneventful except for one retransplant recipient who required prolonged hospitalization (40 days) for rehabilitation. Median hospital stay was 12 days (range 7-40 days). All 10 patients in the C1H group are currently alive and well with stable graft function. No opportunistic infection was observed in these patients to date. We compared six patients with AIH who received C1H to the historic control of 10 recipients with AIH who received conventional immunosuppression (tacrolimus + steroid). The patients treated with C1H showed significantly prolonged rejection-free survival.
  
  
  CONCLUSIONS
  In our preliminary experience, C1H induction was well tolerated in pediatric liver recipients. Rejections-free survival was prolonged among recipients with AIH despite a low level of maintenance immunosuppression.
authors.affiliation: Department of Surgery, University of Miami, Liver and GI Transplant, Miami, Florida 33136, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kato
authors.forename: G
authors.initials: G
authors.lastname: Selvaggi
authors.forename: T
authors.initials: T
authors.lastname: Panagiotis
authors.forename: E
authors.initials: E
authors.lastname: Hernandez
authors.forename: G
authors.initials: G
authors.lastname: McLaughlin
authors.forename: J
authors.initials: J
authors.lastname: Moon
authors.forename: S
authors.initials: S
authors.lastname: Nishida
authors.forename: D
authors.initials: D
authors.lastname: Levi
authors.forename: J
authors.initials: J
authors.lastname: Thompson
authors.forename: N
authors.initials: N
authors.lastname: Halliday
authors.forename: P
authors.initials: P
authors.lastname: Ruiz
authors.forename: A
authors.initials: A
authors.lastname: Tzakis
mesh_terms: D000293:Adolescent; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D019693:Hepatitis, Autoimmune / Q000601:surgery*; D006801:Humans; D008107:Liver Diseases / Q000145:classification / Q000601:surgery; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D011184:Postoperative Period; D012086:Reoperation
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab